These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Lymphokine-activated killer traffic assay and our preliminary clinical results of regional arterial infusion of lymphokine-activated killer cells for renal cell carcinoma. Hayakawa M; Koyama Y; Williams RD; Osawa A Urol Int; 1991; 47 Suppl 1():127-31. PubMed ID: 1949369 [TBL] [Abstract][Full Text] [Related]
9. The in vivo distribution of murine lymphokine activated killer cells in splenectomized host. Chao TY; Chu TM Proc Natl Sci Counc Repub China B; 1990 Dec; 14(4):223-7. PubMed ID: 2101449 [TBL] [Abstract][Full Text] [Related]
10. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. Basse PH APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522 [TBL] [Abstract][Full Text] [Related]
11. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. Basse P; Herberman RB; Nannmark U; Johansson BR; Hokland M; Wasserman K; Goldfarb RH J Exp Med; 1991 Aug; 174(2):479-88. PubMed ID: 1856630 [TBL] [Abstract][Full Text] [Related]
12. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Schwarz RE; Vujanovic NL; Hiserodt JC Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350 [TBL] [Abstract][Full Text] [Related]
14. Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers. Maghazachi AA; Fitzgibbon L Cancer Immunol Immunother; 1990; 31(3):139-45. PubMed ID: 2337903 [TBL] [Abstract][Full Text] [Related]
15. Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery. Ohnishi H; Okuno K; Yasutomi M Cancer Biother; 1993; 8(3):213-22. PubMed ID: 7804361 [TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor. Tjota A; Zhang YQ; Piedmonte MR; Lee CL J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587 [TBL] [Abstract][Full Text] [Related]
17. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. Holladay FP; Heitz T; Wood GW J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119 [TBL] [Abstract][Full Text] [Related]
18. Localization of LAK cells and IL-2-stimulated regional lymph node lymphocytes by regional arterial infusion in renal tumor-bearing rats. Hayakawa M; Lubaroff DM; Williams RD; Osawa A Urol Int; 1993; 50(4):185-91. PubMed ID: 8506587 [TBL] [Abstract][Full Text] [Related]
19. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597 [TBL] [Abstract][Full Text] [Related]
20. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs. Da Pozzo LF; Hough KL; Holder WD Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]